Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Press Releases
December 06, 2021
Abcalis and AdipoGen Life Sciences Partner on Distributing Animal-free Recombinant Monoclonal and Multiclonal Antibodies on the Life Science Research Market
Abcalis GmbH and Adipogen Life Sciences, Inc. (AdipoGen) announced today that they entered into an international marketing and distribution agreement in the field of "animal-free" antibodies for use in the life science research market.
AdipoGen (www.adipogen.com) is a manufacturer and distributes antibodies for the research reagents market. The company is based in the U.S. and Switzerland. Since its inception in 2010, AdipoGen worked at the forefront of producing animal-free recombinant monoclonal antibodies readily available for the research and diagnostic market.
Abcalis GmbH (Abcalis) is a biotech company based in Braunschweig, Germany, focusing on the discovery and development of animal-free recombinant monoclonal and multiclonal antibodies. Their vision is to generate and produce monoclonal and multiclonal antibodies entirely without animal components for a more sustainable manufacturing and reproducible results.
Pascal Milfeit, CEO at Abcalis, and Alessandro Traina, VP of Marketing & New Business Development at AdipoGen announced the deal a strategic collaboration. Abcalis can quickly access the international market through the expertise of AdipoGen and its distribution network, providing their exciting new products and services to the life science research market worldwide. "The product portfolio and know-how of Abcalis in the animal-free recombinant monoclonal and multiclonal antibody field together with our in-house developed antibody portfolio will provide AdipoGen the opportunity to offer a larger product panel to our customer base and the possibility to increase the capacity of custom animal-free antibody development service", said Traina. "We completely trust AdipoGen's longstanding expertise in the life sciences research market. Their exceptional management and skilled employees are going to be the right partner for us to move forward in making our animal-free recombinant monoclonal and multiclonal antibodies available to scientists and researchers worldwide and to increase awareness of our in-house developed animal-free recombinant monoclonal and multiclonal antibody panel and services", said Milfeit.
August 29, 2018
NAICONS and AdipoGen Life Sciences Partner on Commercializing NAICONS’ Rare Antibiotics and Natural Products on the Research Market
NAICONS Srl and Adipogen Life Sciences, Inc (AdipoGen) announced today that they entered into an international commercialization agreement in the field of natural products and rare antibiotics for use in the research market.
AdipoGen (www.adipogen.com) is a manufacturer and international distributor of innovative life sciences research reagents based in the U.S. and Switzerland.
NAICONS Srl is a biotechnological company based in Milan, Italy, focusing on discovery and development of bioactive natural products, particularly novel anti-infective agents. NAICONS’ unique discovery engine is based on its proprietary Strain Library of approximately 45,000 actinomycetes and the multi-disciplinary expertise of a small team of scientists who have filed several patent applications, out-licensed two products and published their research results in peer-reviewed international journals. Based on its know-how in the field of natural products from microorganisms NAICONS also offers specialized services in chemistry and microbiology.
Sonia Maffioli, Director Chemistry at NAICONS, and Alessandro Traina, VP of Marketing at AdipoGen called the deal a strategic collaboration which offers NAICONS the opportunity to share its unique product portfolio of natural products on the international market providing new tools to support life science research worldwide. "We discovered several structural unique microbial products that are likely to act in unprecedented ways. By making them available to the scientific community through AdipoGen, we increase the probability that some of our products will eventually reach the market for a variety of applications" said Maffioli.
August 27, 2018
AdipoGen Life Sciences and Suzhou Bright Scistar Biotechnology (BSBIO) Partner on Commercializing BSBIO’s Human ELISA Kits and Validated Monoclonal Antibodies
Adipogen Life Sciences, Inc. (AdipoGen) announced today that it entered into a R&D and Marketing agreement with Suzhou Bright Scistar Biotechnology Co., Ltd. (BSBIO) to commercialize internationally BSBIO’s proprietary human ELISA Kits and validated monoclonal antibodies in the research fields of cancer and immune checkpoint proteins. In addition the companies will co-develop key biologicals with therapeutic and diagnostic potential.
AdipoGen (www.adipogen.com) is a manufacturer and international distributor of innovative life science research reagents and of GMP-grade proteins (enhanced cytokines) based in the U.S. and Switzerland. BSBIO is based in Suzhou, China and works closely with the Soochow University Medical and Biological Technology Institute and Jiangsu Clinical Immunology Institute. BSBIO’s 20 researchers continue to develop clinically relevant human ELISA Kits and validated monoclonal antibodies to accelerate the advancement of research in immunology and immunotherapy.
Xueguang Zhang, Chairman and Chief Scientist of BSBIO called the deal a very strategic collaboration which offers BSBIO more exposure in the Chinese market and more access to the international market. Combining the R&D efforts of AdipoGen and BSBIO will provide economical, innovative and state of the art tools supporting life science research, worldwide.